EA201100464A1 - Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение - Google Patents

Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение

Info

Publication number
EA201100464A1
EA201100464A1 EA201100464A EA201100464A EA201100464A1 EA 201100464 A1 EA201100464 A1 EA 201100464A1 EA 201100464 A EA201100464 A EA 201100464A EA 201100464 A EA201100464 A EA 201100464A EA 201100464 A1 EA201100464 A1 EA 201100464A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
pharmaceutical composition
application
hyperproliferative diseases
biotechnology
Prior art date
Application number
EA201100464A
Other languages
English (en)
Other versions
EA017179B1 (ru
Inventor
Владимир Константинович БОЖЕНКО
Original Assignee
Ооо "Метамакс" (Ооо "Метамах")
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ооо "Метамакс" (Ооо "Метамах") filed Critical Ооо "Метамакс" (Ооо "Метамах")
Priority to EA201100464A priority Critical patent/EA201100464A1/ru
Priority to EP11863085.4A priority patent/EP2712621B1/en
Priority to PCT/RU2011/000343 priority patent/WO2012138246A1/ru
Priority to US14/002,860 priority patent/US8969515B2/en
Priority to JP2014503623A priority patent/JP5852731B2/ja
Publication of EA017179B1 publication Critical patent/EA017179B1/ru
Publication of EA201100464A1 publication Critical patent/EA201100464A1/ru
Priority to US14/599,426 priority patent/US20150174191A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к области биотехнологии и медицины, в частности к фармацевтической композиции, обладающей антипролиферативной активностью и способу лечения онкологических заболеваний, включающему введение указанного химерного пептида нуждающемуся в таком лечении млекопитающему. Задачей изобретения является разработка препарата, эффективно проникающего в клетки-мишени и обладающего высоким цитостатическим и цитотоксическим действием.
EA201100464A 2011-04-06 2011-04-06 Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение EA201100464A1 (ru)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EA201100464A EA201100464A1 (ru) 2011-04-06 2011-04-06 Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение
EP11863085.4A EP2712621B1 (en) 2011-04-06 2011-05-20 Pharmaceutical composition for treating hyperproliferative diseases
PCT/RU2011/000343 WO2012138246A1 (ru) 2011-04-06 2011-05-20 Фармацевтическая композиция для лечения гиперпролиферативных заболеваний
US14/002,860 US8969515B2 (en) 2011-04-06 2011-05-20 Pharmaceutical composition for treating hyperproliferative diseases
JP2014503623A JP5852731B2 (ja) 2011-04-06 2011-05-20 高増殖性疾患治療のための医薬組成物
US14/599,426 US20150174191A1 (en) 2011-04-06 2015-01-16 Pharmaceutical composition for treating hyperproliferative diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201100464A EA201100464A1 (ru) 2011-04-06 2011-04-06 Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение

Publications (2)

Publication Number Publication Date
EA017179B1 EA017179B1 (ru) 2012-10-30
EA201100464A1 true EA201100464A1 (ru) 2012-10-30

Family

ID=46969422

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100464A EA201100464A1 (ru) 2011-04-06 2011-04-06 Фармацевтическая композиция для лечения гиперпролиферативных заболеваний и её применение

Country Status (5)

Country Link
US (2) US8969515B2 (ru)
EP (1) EP2712621B1 (ru)
JP (1) JP5852731B2 (ru)
EA (1) EA201100464A1 (ru)
WO (1) WO2012138246A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028151B1 (ru) * 2013-04-03 2017-10-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "МетаМакс" (ООО "МетаМакс") Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519275D0 (en) * 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
AU745749B2 (en) * 1998-05-15 2002-03-28 Cancer Advances, Inc. Combination therapy for the treatment of tumors
EP1345957A2 (en) * 2000-12-20 2003-09-24 Novartis AG Inhibitors of the e2f-1/cyclin interaction for cancer therapy
RU2297241C2 (ru) * 2004-11-22 2007-04-20 Государственное учреждение Российский научный центр рентгенорадиологии Министерства здравоохранения и социального развития Химерный белок для лечения злокачественных лимфом
US8173604B2 (en) * 2006-05-24 2012-05-08 Albert Einstein College Of Medicine Of Yeshiva University Inhibition of Skp2-cyclin a interaction
CN101801401A (zh) * 2007-03-16 2010-08-11 佛罗里达大学研究基金会 激酶蛋白质结合抑制剂
EP2178531A4 (en) * 2007-07-02 2012-01-11 Yu Ming METHODS AND COMPOSITIONS, TARGETS FOR COMBINED CANCER TREATMENTS
RU2369402C1 (ru) * 2008-04-17 2009-10-10 Федеральное Государственное Учреждение "Российский научный центр рентгенорадиологии Федерального агентства по высокотехнологичной медицинской помощи" Химерный пептид для лечения эпителиальных и мезенхимальных злокачественных новообразований

Also Published As

Publication number Publication date
US8969515B2 (en) 2015-03-03
US20140051644A1 (en) 2014-02-20
JP2014510135A (ja) 2014-04-24
WO2012138246A1 (ru) 2012-10-11
US20150174191A1 (en) 2015-06-25
JP5852731B2 (ja) 2016-02-03
EA017179B1 (ru) 2012-10-30
EP2712621B1 (en) 2018-08-08
EP2712621A4 (en) 2014-10-29
EP2712621A1 (en) 2014-04-02

Similar Documents

Publication Publication Date Title
PH12016501790B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201500207A1 (ru) Гетероароматические соединения в качестве ингибиторов втк
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
EA201991484A1 (ru) Лекарственные формы энзалутамида
EA201500132A1 (ru) Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний
MX353608B (es) Anticuerpo modificado en el que el tema que comprende residuos de cisteina esta ligado, conjugado de farmaco de anticuerpo modificado que comprende el anticuerpo modificado y metodo de produccion para el mismo.
TW201129382A (en) Antibody formulation and therapeutic regimens
UA111579C2 (uk) ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
IN2014MN00986A (ru)
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
EA201590144A1 (ru) Rspo3-связывающие агенты и их применение
EA201171285A1 (ru) Новая технология изготовления диклофенака
EA201300137A1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний, связанных с нейродегенеративными зоболеваниями
IN2015DN00450A (ru)
MA40057A (fr) Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants
EA201591925A1 (ru) Терапевтические композиции и их применение
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112017025698A2 (pt) composições e métodos para inibir a expressão do gene de hif2alfa
EA201491500A1 (ru) Способы лечения фиброза
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment